大宏立：10月23日召开董事会会议

Group 1 - The core point of the article is that Dahongli (SZ 300865) held its third meeting of the fifth board of directors on October 23, 2025, to discuss the proposal for the reappointment of the accounting firm for the 2025 fiscal year [1] - For the fiscal year 2024, Dahongli's revenue composition is 98.51% from the mining machinery manufacturing industry and 1.49% from other businesses [1] - As of the report date, Dahongli has a market capitalization of 3.2 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting a hot secondary market in biomedicine [1] - There is a discussion on why the primary market is experiencing a fundraising slowdown despite the active secondary market [1]